National Institute of Advanced Industrial Science and Technology

National Center for Global Health and Medicine

Sysmex Corporation

Nagoya University

The University of Toyama

Public University Corporation Nagoya City University

Science & Technology Corporation

Glycobiomarker Leading Innovation Co., Ltd.

National Institute of Advanced Industrial

Nagoya City University

Maki Sogabe

Hisashi Narimatsu

Yuzuru Ikehara

Akira Togayachi

Atsushi Kuno

Masashi Mizokami

Hiroyuki Kaji

Yasuhito Tanaka

Toru Nakanishi

Hayao Nakanishi

Hiromichi Sawaki

Tomomi Kubota

Takashi Sato

Yasunori Chiba

Jun Hirabayashi

Shinya Nagai

Youichi Takahama

Takashi Ohkura

Chikayuki Tsuruno

Makoto Ochou

Kiyoaki Ito

Shunsuke Matsubara

Toshihide Shikanai

Takashi Angata

Takashi Kagawa

Kiyohiko Angata

Hiroki Shimizu

Takanori Wagatsuma

Masaaki Korenaga

Kazuto Tajiri

Tatsuhiko Ozawa

An examination system that recognizes a glycosylated antigen in Dane particles of hepatitis B virus (HBV) and a neutralizing antibody that recognizes the glycosylated antigen and that exhibits an infection-inhibiting activity. It was elucidated that Dane particles are associated with specific glycan structures, and this enabled the construction of a new detection system for infectious, i.e., nucleic acid-containing, hepatitis B virus particles and the provision of a neutralizing antibody that recognizes a glycosylated antigen and that exhibits an infection-inhibiting activity.

Method for efficiently inducing antibody, antibody and detection system for hepatitis virus

It is intended to find a highly specific epithelial ovarian cancer marker and to provide an antibody capable of specifically recognizing and detecting the marker or a fragment of the antibody. The present invention provides an anti-&#x3b2;1,6-N-acetylglucosaminyltransferase 5B antibody for diagnosis of epithelial ovarian cancer, i.e., an antibody for detection of a glycosyltransferase &#x3b2;1,6-N-acetylglucosaminyltransferase 5B as an epithelial ovarian cancer marker. The antibody recognizes, as an epitope, a part of a polypeptide of the enzyme consisting of the amino acid sequence represented by SEQ ID NO: 1.

Antibody for detecting epithelial ovarian cancer marker and method for diagnosing epithelial ovarian cancer

The present invention provides an antibody capable of specifically recognizing and detecting the highly specific cancer marker with respect to the epithelial ovarian cancer, or a fragment of the antibody. The present invention provides an anti-&#x3b2;1,3-N-acetylglucosaminyltransferase 3 antibody for diagnosis of epithelial ovarian cancer, i.e., an antibody for detection of a glycosyltransferase &#x3b2;1,3-N-acetylglucosaminyltransferase 3 as an epithelial ovarian cancer marker. The antibody recognizes, as an epitope, a part of a polypeptide of the enzyme consisting of the amino acid sequence represented by SEQ ID NO: 1.

The present invention is directed to developing a glycan markers capable of detecting a hepatic disease, and more specifically to developing a glycan marker indicating a hepatic disease-state. Furthermore, the present invention is also directed to developing a glycan marker capable of distinguishing hepatic disease-states with the progress of hepatocarcinoma. The present inventors identified, among the serum glycoproteins, glycopeptides and glycoproteins in which a glycan structure specifically changes due to a hepatic diseases including hepatocarcinoma and provide these as novel glycan markers (glycopeptide and glycoprotein) specific to hepatic disease-states.

Glycan markers as measure of disease state of hepatic diseases

An object of the present invention is to provide a method for measuring a glycan-marker glycoprotein, by which liver disease can be detected with higher accuracy than is possible with conventional methods. Also, an object of the present invention is to provide a method for examining liver disease, by which liver disease can be detected with higher accuracy than is possible with conventional methods. Disclosed is a method for measuring at least one glycoprotein selected from alpha-1-acid glycoprotein (AGP) and Mac-2-binding protein (M2BP) contained in a sample collected from a subject, comprising: measuring AGP binding to a first lectin selected from AOL and MAL, when the glycoprotein is AGP; and measuring M2BP binding to a second lectin selected from WFA, BPL, AAL, RCA120, and TJAII, when the glycoprotein is M2BP.

Method for measuring glycoprotein, method for examining liver disease, reagent for quantitative determination of glycoprotein, and glycan-marker glycoprotein as an index for clinical conditions of liver disease

Growing community of inventors

Ibaraki, Japan

Maki Sogabe